Table 4 Characteristics of patients with HCV according to TM6SF2 polymorphisms (n = 362)
CC | CT/TT% / (n) or mean ± SD | P value | |
|---|---|---|---|
Age (years) | 55.17 ± 12.66 | 48.88 ± 11.87 | 0.002* |
Men /Women (n) | 44.1% (142)/55.9% (180) | 52.5% (21)/47.5% (19) | 0.313 |
Race | |||
White | 76.7% (247) | 75% (30) | 0.757 |
Multiracial (Brown) | 13.7% (44) | 17.5% (7) | |
Black | 9.6% (31) | 7.5% (3) | |
Type 2 diabetes (n) | 24.4% (77) | 15% (6) | 0.186 |
Dyslipidemia (n) | 21.6% (68) | 10% (4) | 0.086 |
High-blood pressure (n) | 45.3% (143) | 27.5% (11) | 0.032* |
Obesity (BMI ≥ 30) (n) | 31.6% (100) | 15% (6) | 0.030* |
BMI | 27.7 ± 5.21 | 26.59 ± 3.24 | 0.274 |
Metabolic syndrome (n) | 25.3% (80) | 7.7% (3) | 0.014* |
Hypothyroidism (n) | 17.4% (55) | 17.5% (7) | 0.988 |
Previous alcohol use (n) | 8.2% (26) | 10% (4) | 0.760 |
HOMA-IR value ≥ 2.5 (n) | 53.1% (171) | 50% (20) | 0.710 |
HOMA-IR | 3.26 ± 4.31 | 2.69 ± 3.86 | 0.414 |
AST (U/L) | 63.11 ± 51.51 | 60.65 ± 42.02 | 0.897 |
ALT (U/L) | 68.76 ± 52.21 | 68.33 ± 44.48 | 0.760 |
Alkaline phosphatase (U/L) | 84.19 ± 35.34 | 74.05 ± 27.46 | 0.041* |
GGT (U/L) | 104.16 ± 113.22 | 84.26 ± 83.48 | 0.276 |
Creatinine (mg/dL) | 0.87 ± 0.33 | 1.01 ± 1.57 | 0.091 |
Total cholesterol (mg/dL) | 158.24 ± 35.06 | 147.33 ± 42.32 | 0.036* |
HDL (mg/dL) | 52.27 ± 16.12 | 49.67 ± 15.88 | 0.516 |
LDL (mg/dL) | 85.69 ± 30.67 | 79.31 ± 36.08 | 0.117 |
Triglycerides (mg/dL) | 103.05 ± 54.03 | 91.05 ± 37.1 | 0.205 |
Liver histology | |||
Fibrosis (n) 0–1 | 33.9% (109) | 50% (20) | |
2–4 | 66.1% (213) | 50% (20) | 0.044* |
Inflammation (n) 0–1 | 46.7% (122) | 43.2% (16) | |
2–3 | 53.3% (139) | 56.8% (21) | 0.689 |
Steatosis (n) 0 | 45.3% (145) | 40% (16) | |
1–3 | 54.7% (175) | 60% (24) | 0.524 |